OncoHost, company involved in host response profiling for improved personalised cancer therapy, announced yesterday that it is opening its state-of-the-art high throughput proteomics laboratory for host response analysis.

The lab joins a chosen group of specialised proteomics laboratories around the globe and is the first industrial-level lab intended for human host response in Israel. It can create proteomic signatures by evaluating more than 1,000 proteins using a very low volume of plasma. The analysis is utilised for prediction of response to treatment and examination of the biological processes and key proteins that are associated with non-responsiveness to treatment. It is operating in research mode.

Ofer Sharon, MD, CEO of OncoHost, said, 'Profiling of host response to immunotherapy addresses a major challenge in oncology today – understanding why treatment helps some patients but not others. By combining OncoHost's proprietary technology with proteomic analysis, we are able to predict how individual patients may respond to treatment. This is the first step towards developing successful personalised cancer treatment plans.'